<DOC>
	<DOCNO>NCT01831804</DOCNO>
	<brief_summary>This randomize , placebo-controlled , single-blind ( subject investigator blind , GSK internal personnel blind ) , parallel-group , two part ( Part A , Part B ) trial healthy volunteer subject diabetic foot ulcer . Part A designed evaluate single application GSK1278863 one cohort healthy volunteer ( intact skin ) approximately 3 cohort diabetic subject . Part B design evaluate first single , repeat application GSK1278863 diabetic , clinic subject home . Part B include approximately 3 cohort concentration drug apply determine pharmacokinetic data Part A early cohort Part B .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Study Single Repeated Doses Topical GSK1278863</brief_title>
	<detailed_description />
	<mesh_term>Diabetic Foot</mesh_term>
	<criteria>Inclusion Criteria Healthy Volunteers ( Part A Cohort 1 ) Alanine aminotransferase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . [ Single ] correct QT interval ( QTc ) &lt; 450 millisecond ( msec ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test electrocardiogram ( ECGs ) . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GlaxoSmithKline ( GSK ) Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Subjects hemoglobin ( Hb ) value high ULN normal range always exclude enrollment . Male female 18 90 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential ( postmenopausal premenopausal female document tubal ligation hysterectomy ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method protocol . Male subject female partner childbearing potential must agree use one contraception method list protocol . Inclusion Criteria DFU Subjects must meet healthy volunteer inclusion criterion follow Diagnosed Type I Type II diabetes mellitus . Glycosylated haemoglobin ( HbA1c ) &lt; =12 % . QTc &lt; 480 msec subject bundle branch block . Lower extremity diabetic foot ulcer 30 364 day ' duration . DFU 1 centimeter square ( cm ^2 ) 20 cm^2 screening . Presence least one DFU meet follow criterion : ( ) . Ulcer diagnose fullthickness , neuropathic DFU locate distal malleolus ( exclude ulcer toe include heel ) . ( b ) . There minimum 2 cm margin qualify study ulcer ulcer specify foot . ( c ) . Ulcer size ( area ) &gt; =1 cm^2 &lt; =12 cm^2 ( postdebridement time randomization ) . ( ) . Wagner Grade 1 . ( e ) . Depth &lt; =5 millimeter ( mm ) capsule , tendon bone expose tunneling , undermine , sinus tract . Note : If subject one qualifying DFU , ulcer designate study ulcer discretion Investigator . Nonstudy ulcer treat course study treat moist wound therapy Standard Care ( SOC ) identify study . Adequate vascular perfusion affect limb within 30 day screen , define least one following : ( ) Transcutaneous oxygen partial pressure ( TcPO2 ) &gt; 35 millimeter mercury ( mmHg ) . ( b ) AnkleBrachial Index ( ABI ) &gt; =0.6 &lt; =1.2 , confirm TcPO2 &gt; 35 mmHg . ( c ) Toe pressure ( plethysmography ) &gt; 50 mmHg . ( ) Doppler ultrasound ( biphasic triphasic waveform ) consistent adequate blood flow affect extremity , determine SOC . Exclusion Criteria Healthy Volunteers ( Part A Cohort 1 ) A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History malignancy within 5 year Screening strong family history cancer ( e.g. , familial cancer disorder ) , exception squamous cell basal cell carcinoma skin definitively treat . A history drug alcohol abuse , history regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 gram alcohol : 12 ounce ( 360 mililiter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . A positive test human immunodeficiency virus ( HIV ) antibody . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives ( whichever longer ) . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GlaxoSmithKline ( GSK ) Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500mL within 56 day period . Pregnant female determine positive urine human chorionic gonadotropin test screen prior dosing . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . Exclusion Criteria DFU Subjects Healthy volunteer exclusion apply DFU subject addition follow : Subjects ulcer accompany infected cellulitis , osteomyelitis , clinical sign symptom infection , Gangrene part affect limb , Active Charcot 's foot study limb , Planned vascular surgery , angioplasty thrombolysis , Ulcers involve exposure tendon , bone , joint capsule ( It acceptable ulcer extend dermis subcutaneous tissue presence granulation tissue ) , Ulcers due nondiabetic etiology . Any unstable vascular syndrome ( transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) , unstable angina , acute myocardial infarction ( MI ) acute coronary syndrome event ( ACS ) and/or major change ( per investigator 's judgment ) relate medication within 6 month prior randomization . History malignancy within 5 year screen strong family history cancer ( e.g . familial cancer disorder ) , exception squamous cell basal cell carcinoma skin definitively treat . Other clinically significant cardiovascular , pulmonary , renal , endocrine , hepatic , neurological , psychiatric , immunological , gastrointestinal , hematological , metabolic disease , opinion Investigator GSK Medical Monitor , stabilize may otherwise impact result study . Patients active treatment retinal neovascularization ( e.g. , diabetic proliferative retinopathy age relate macular degeneration ) within 6 month randomization . Patients undergoing hemodialysis . History venous thrombosis define deep vein thrombosis , pulmonary embolism venous thrombotic condition within 1 year prior screen . Active peptic , duodenal , esophageal ulcer disease gastrointestinal bleeding , within 1 year prior screen . Subjects platelet count &lt; 100,000/mm^3 screening . Subjects International Normalized Ratio ( INR ) &gt; 1.5 screening . Subjects hemoglobin level genderspecific upper limit normal screening . Subjects history nontraumatic joint inflammation ( exception inflammation due osteoarthritis ) . Patients know pulmonary hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>diabetic foot ulcer</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>ischemic</keyword>
</DOC>